Pharming (PHAR) EBIT (QoQ) (2020 - 2026)
Analysis
Pharming (PHAR) EBIT (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Pharming | 794.84 Mn | 635.34 Mn | 141.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.57% |
| Mar 31, 2026 | -79,032,358.06% |
| Dec 31, 2025 | -100.00% |
| Mar 31, 2025 | 54.25% |
| Dec 31, 2024 | -473.17% |
| Sep 30, 2024 | 121.10% |
| Jun 30, 2024 | -19.22% |
| Mar 31, 2024 | -1,581.82% |
| Dec 31, 2023 | -42.35% |
| Sep 30, 2023 | -64.00% |
| Jun 30, 2023 | 138.79% |
| Mar 31, 2023 | -148.11% |
| Dec 31, 2022 | 264.10% |
| Sep 30, 2022 | -56.18% |
| Jun 30, 2022 | 535.71% |
| Mar 31, 2022 | 119.14% |
| Dec 31, 2021 | -771.65% |
| Sep 30, 2021 | -115.46% |
| Jun 30, 2021 | 72.25% |
| Mar 31, 2021 | -82.35% |